APA Alıntı

Fleischmann, R., van Adelsberg, J., Lin, Y., Castelar‐Pinheiro, G. d. R., Brzezicki, J., Hrycaj, P., . . . Burmester, G. R. (2017). Sarilumab and Nonbiologic Disease‐Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors. Arthritis Rheumatol.

Chicago Stili Alıntı

Fleischmann, Roy, et al. "Sarilumab and Nonbiologic Disease‐Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors." Arthritis Rheumatol 2017.

MLA Alıntı

Fleischmann, Roy, et al. "Sarilumab and Nonbiologic Disease‐Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors." Arthritis Rheumatol 2017.

Uyarı: Bu alıntı herzaman %100 doğru olmayabilir..